I am interested to know how they will obtain capital to proceed with trials of all these clinical stage assests. Is SYNBV going to raise capital? Because there is no way Adalta can raise anything substantial at these levels.
Ann: SYNThesis BioVentures MoU for cellular immunotherapies, page-51
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.21M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55002 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 197631 | 1 |
View Market Depth
| Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
| 1AD (ASX) Chart |
Day chart unavailable